ERBB2 and breast cancer: This approval was based on the findings of a phase III randomized clinical trial that looked at the efficacy and safety of neratinib after adjuvant therapy with neoadjuvant and trastuzumab in patients with HER2-positive early-stage (I-III) breast cancer.